New Delhi: Aurobindo Pharma on Saturday said its consolidated net profit for the first quarter ended June 2024 rose 61 percent year-on-year to Rs. 919 crore, aided by strong sales across markets. The Hyderabad-based drug maker in the April-June quarter of last fiscal posted Rs. 571 crore in net profit.
Income from operations increased to Rs. 7,567 crore which in the year-ago period was Rs. 6,851 crore, the drugmaker said in a statement.
“We are pleased with our continued strong performance this quarter, with significant top-line growth across all our business segments,” said K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma.
Profitability was sustained through improved gross margins and operational efficiencies, along with ramping up our recently commercialized plants, he added.
“We are confident in our ability to achieve our growth targets for FY25,” Reddy said.
(You can now subscribe to our ETMarkets WhatsApp channel)
